Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immediate hypersensitivity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Immediate hypersensitivity. Displaying page 1 of 1.
    EudraCT Number: 2022-003703-16 Sponsor Protocol Number: GR-2021-12375001 Start Date*: Information not available in EudraCT
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: The effect of phoSPHocreatine on mEdical emergency team (met) tREated patients: a randomized clinical trial protocol - SPHERE.
    Medical condition: Patients with worsening clinical condition requiring MET intervention and in general ward
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10045240 Type I hypersensitivity PT
    23.0 10047065 - Vascular disorders 10083659 Hypotensive crisis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003248-36 Sponsor Protocol Number: 61383082 Start Date*: 2011-09-30
    Sponsor Name:Central Military Hospital
    Full Title: The clinical significance of epigenetic factors research to refine the diagnosis, estimate prognosis and risk of recurrence after curative pancreatic cancer resection.
    Medical condition: The aim of the study to estimate frequence of epigenetics changes in pancreatic cancer and to assess the signidicance of apllication of the intravenous contrast agent during endosonography to bette...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10016335 Feeling hot and cold LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037872 Rash NOS LLT
    14.0 10037175 - Psychiatric disorders 10032168 Other insomnia LLT
    14.0 10007541 - Cardiac disorders 10008481 Chest pain - cardiac LLT
    14.0 10017947 - Gastrointestinal disorders 10064907 Functional abdominal pain LLT
    14.0 10029205 - Nervous system disorders 10048324 Dizziness aggravated LLT
    14.0 10029205 - Nervous system disorders 10033777 Paraesthesia distal LLT
    14.0 10022891 - Investigations 10050786 Fasting blood glucose increased LLT
    14.0 10018065 - General disorders and administration site conditions 10022096 Injection site reaction NOS LLT
    14.0 10021881 - Infections and infestations 10034838 Pharyngitis NOS LLT
    14.0 10018065 - General disorders and administration site conditions 10016259 Fatigueability LLT
    14.0 10021428 - Immune system disorders 10020762 Hypersensitivity type I LLT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10048412 Back pain aggravated LLT
    14.0 10021428 - Immune system disorders 10020756 Hypersensitivity reaction LLT
    14.0 10017947 - Gastrointestinal disorders 10028822 Nauseated LLT
    14.0 10047065 - Vascular disorders 10048347 Flushing aggravated LLT
    14.0 10029205 - Nervous system disorders 10024857 Loss of consiousness LLT
    14.0 10029205 - Nervous system disorders 10019218 Headache NOS LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037096 Pruritus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003699-60 Sponsor Protocol Number: KIBB01 Start Date*: 2018-09-28
    Sponsor Name:Karolinska Institutet
    Full Title: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal...
    Medical condition: Treatment of Osteogenesis Imperfecta (OI) type III and severe type IV.
    Disease:
    Population Age: In utero, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000276-10 Sponsor Protocol Number: FAST2015 Start Date*: 2015-07-02
    Sponsor Name:FAST Consortium under EU 7. FWP
    Full Title: FAST – Food Allergy Specific ImmunoTherapy A multinational phase IIb study to investigate the efficacy and safety of subcutaneous immunotherapy with a modified fish- parvalbumin given in single ri...
    Medical condition: Food allergy to fish
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed) DK (Completed) GR (Ongoing) NL (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011737-27 Sponsor Protocol Number: BASALIT Start Date*: 2010-01-07
    Sponsor Name:University Leipzig
    Full Title: A multi centre randomised placebo-controlled double-blind clinical trial for the evaluation of efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic der...
    Medical condition: Immediate type allergy to soy proteins in patients with birch pollinosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021428 - Immune system disorders 10057630 Protein allergy LLT
    13.1 10021428 - Immune system disorders 10066093 Birch pollen allergy LLT
    13.1 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001537-92 Sponsor Protocol Number: RHMCHI0714 Start Date*: 2014-07-02
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE 2 study
    Medical condition: Children aged 24 months to (and including) 17 years with IgE-mediated food allergy to egg protein
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004870 10014315 Egg allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002031-26 Sponsor Protocol Number: RHMCHI065 Start Date*: 2013-06-25
    Sponsor Name:University Hospitals Southampton NHS Foundation Trust
    Full Title: Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE study
    Medical condition: Children aged 24 months to (and including) 17 years with IgE-mediated food allergy to egg protein
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004870 10014315 Egg allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004378-92 Sponsor Protocol Number: EdomTHC Start Date*: 2019-05-27
    Sponsor Name:Fundació Clínic per la Recerca Biomèdica
    Full Title: Effect of cannabinoids (THC / CBD) on hyperalgesia in patients with deep endometriosis
    Medical condition: Deep endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003514-91 Sponsor Protocol Number: V59P10 Start Date*: 2014-09-30
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Compare the Safety of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with that of a Licensed Meningococcal ACWY P...
    Medical condition: Novartis Meningococcal ACWY Conjugate Vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis A, C, W-135 and Y.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-000430-20 Sponsor Protocol Number: V44P9S Start Date*: 2005-06-02
    Sponsor Name:Chiron Behring GmbH & Co KG
    Full Title: A phase III, multicenter, uncontrolled, open label study to demonstrate safety, tolerability and immunogenicity of the Chiron Behring preservative free inactivated split influenza vaccine using the...
    Medical condition: no medical condition; healthy volunteers will be recruited into clinical trial for annual approval of Influenza vaccine with new strain composition according to WHO and EMEA recommendation and CPMP...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001237-41 Sponsor Protocol Number: NLCG-2013.1 Start Date*: 2013-06-05
    Sponsor Name:Norwegian University of Science and Technology
    Full Title: A Randomized Phase III Study Comparing Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer
    Medical condition: Advanced non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003670-32 Sponsor Protocol Number: REFLECT Start Date*: Information not available in EudraCT
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB)
    Medical condition: Recessive dystrophic epidermolysis bullosa (RDEB)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005115-16 Sponsor Protocol Number: FORMA-04 Start Date*: 2020-04-22
    Sponsor Name:Octapharma AG
    Full Title: Prospective, open-label, uncontrolled, Phase III study to assess the efficacy, safety, and pharmacokinetics of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during an...
    Medical condition: Congenital fibrinogendeficiency
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-005385-12 Sponsor Protocol Number: GI-5005-02 Start Date*: 2008-04-11
    Sponsor Name:GlobeImmune, Inc.
    Full Title: A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces cerevisiae Expressing a Hepatitis ...
    Medical condition: The genotype 1 Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057212 Hepatitis viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005161-72 Sponsor Protocol Number: V59P20 Start Date*: 2014-12-05
    Sponsor Name:Novartis Vaccines & Diagnostics
    Full Title: A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with One Dose of Licensed Meningococc...
    Medical condition: Prophylaxis for Neisseria meningitidis serogroup A, C, W, and Y
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004179-33 Sponsor Protocol Number: I8F-MC-GPGB Start Date*: 2017-06-15
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of Once-Weekly LY3298176 Compared with Placebo and Dulaglutide in Patients with Type 2 Diabetes Mellitus
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005386-35 Sponsor Protocol Number: GI-4000-02 Start Date*: 2008-10-07
    Sponsor Name:GlobeImmune, Inc.
    Full Title: A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant...
    Medical condition: Pancreatic Cancer, post resection R0/R1 status, with tumor sequence confirmation of Ras mutations
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004310-33 Sponsor Protocol Number: CAR4SAR Start Date*: 2022-02-21
    Sponsor Name:Dr. Antonio Pérez Martínez
    Full Title: A Phase I Trial of Memory T Cells Expressing an ANTI-NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults with Advanced Sarcoma
    Medical condition: Advanced Sarcoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020841-29 Sponsor Protocol Number: ADAPT Start Date*: 2011-07-07
    Sponsor Name:King`s College London [...]
    1. King`s College London
    2. Guy`s & St Thomas` NHS Foundation Trust
    Full Title: The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema
    Medical condition: Severe eczema in children
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003641 Atopic eczema LLT
    19.0 100000004858 10014189 Eczema allergic atopic LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003504-79 Sponsor Protocol Number: V59P13 Start Date*: 2014-10-24
    Sponsor Name:Novartis Vaccines & Diagnostics, Inc.
    Full Title: A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Investigational Meningococcal ACWY Conjugate Vaccine when One Dose is Administered t...
    Medical condition: Novartis Meningococcal ACWY conjugate vaccine is intended for prevention of meningitis and septicemia caused by Neisseria meningitidis serogroups A, C, W and Y.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10027280 Meningococcal sepsis PT
    17.1 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    17.1 10021881 - Infections and infestations 10027276 Meningococcal meningitis LLT
    17.1 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    17.1 10021881 - Infections and infestations 10040081 Septicaemia meningococcal LLT
    17.1 10021881 - Infections and infestations 10040048 Sepsis meningococcal LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Nov 01 11:28:17 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA